BPC-157 · research summary

Acute Compartment Syndrome and Intra-Abdominal Hypertension, Decompression, Current Pharmacotherapy, and Stable Gastric Pentadecapeptide BPC 157 Solution.

Pharmaceuticals (Basel, Switzerland) · 2025. Summary drawn from the study's full text. Each statement is followed by the exact sentence it comes from. This is a research summary, not medical advice.

Study type

Review of animal studies on pharmacotherapies for abdominal compartment syndrome and intra-abdominal hypertension
“In this study, pharmacotherapies of abdominal compartment syndrome (ACS) and intra-abdominal hypertension (IAH) in animal studies were reviewed from the perspective of ACS/IAH as failed cytoprotection issues, as non-specific injuries, and from the point of view of the cytoprotection concept as resolution.”

Subjects

Animals, primarily rats, with some studies in other species
“The recent introduction of the stable gastric pentadecapeptide BPC 157 as a possible therapy for acute ACS [7,8] follows extensive basic research of many agents, primarily in rats [30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62] (Table 1), but also in other species [121,122,123,124,125,126,127,128,129,130,131,132] (Table 2).”

Reported findings

Most reviewed agents showed limited effectiveness, primarily in prophylactic application, mild/moderate IAH, and single-organ targets.
“Generally, the reported agents not aligned with cytoprotection align with current pharmacotherapy limitations and have (non-)confirmed effectiveness, mostly in only one organ, mild/moderate IAH, prophylactic application, and provide only a tentative resolution.”
BPC 157 therapy was linked to the activation of collateral bypassing pathways, specifically azygos vein direct blood flow delivery, to counteract vessel failure.
“BPC 157 therapy rapidly activates collateral bypassing pathways, and, in ACS and IAH, and later, in reperfusion, there is a “bypassing key” (i.e., azygos vein direct blood flow delivery).”

Limitations stated by the authors

Current support is primarily preclinical, and further human trials are essential to confirm therapeutic potential.
“Finally, since this paper at times implies strong therapeutic potential for BPC 157 in humans, it should be noted that, while encouraging, this should be carefully framed within the context of the early-stage nature of clinical evidence, given that the current support is primarily preclinical, and that further human trials are essential.”

Source: PubMed 40573261 · DOI 10.3390/ph18060866 · all study summaries

Study type

Review of animal studies on pharmacotherapies for abdominal compartment syndrome and intra-abdominal hypertension

“In this study, pharmacotherapies of abdominal compartment syndrome (ACS) and intra-abdominal hypertension (IAH) in animal studies were reviewed from the perspective of ACS/IAH as failed cytoprotection issues, as non-specific injuries, and from the point of view of the cytoprotection concept as resolution.”

Subjects

Animals, primarily rats, with some studies in other species

“The recent introduction of the stable gastric pentadecapeptide BPC 157 as a possible therapy for acute ACS [7,8] follows extensive basic research of many agents, primarily in rats [30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62] (Table 1), but also in other species [121,122,123,124,125,126,127,128,129,130,131,132] (Table 2).”

Reported findings

Most reviewed agents showed limited effectiveness, primarily in prophylactic application, mild/moderate IAH, and single-organ targets.

“Generally, the reported agents not aligned with cytoprotection align with current pharmacotherapy limitations and have (non-)confirmed effectiveness, mostly in only one organ, mild/moderate IAH, prophylactic application, and provide only a tentative resolution.”

BPC 157 therapy was linked to the activation of collateral bypassing pathways, specifically azygos vein direct blood flow delivery, to counteract vessel failure.

“BPC 157 therapy rapidly activates collateral bypassing pathways, and, in ACS and IAH, and later, in reperfusion, there is a “bypassing key” (i.e., azygos vein direct blood flow delivery).”

Limitations stated by the authors

Current support is primarily preclinical, and further human trials are essential to confirm therapeutic potential.

“Finally, since this paper at times implies strong therapeutic potential for BPC 157 in humans, it should be noted that, while encouraging, this should be carefully framed within the context of the early-stage nature of clinical evidence, given that the current support is primarily preclinical, and that further human trials are essential.”